Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBRT + TACE + Sorafenib vs Sorafenib in Unresectable HCC with PVTT
NCT04387695Phase 3Unknown
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Apr 2020
- Primary completion
- Aug 2023
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in hepatocellular carcinoma (HCC) and Portal vein tumor thrombus (PVTT) (2 arms), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Progression-Free Survival at 12 weeks. Status: unknown.
02
Conditions
hepatocellular carcinoma (HCC)Portal vein tumor thrombus (PVTT)
Beyond the preview
Go deeper on NCT04387695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04387695.